Neuromyelitis Optica (Devic’s Syndrome) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Neuromyelitis Optica (Devic’s Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions.
Neuromyelitis optica (NMO), also known as Devic’s syndrome, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord, or nerves. NMO is an autoimmune condition where the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness, and bladder/bowel problems.
The Neuromyelitis Optica (Devic’s Syndrome) drugs in development market research report provide comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Neuromyelitis Optica (Devic's Syndrome) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 43 molecules, with 40 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Neuromyelitis Optica (Devic’s Syndrome) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Neuromyelitis Optica (Devic’s Syndrome) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Neuromyelitis Optica (Devic’s Syndrome) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
4B Technologies (Suzhou) Co LtdAccendatech Co Ltd
Aeterna Zentaris Inc
AffaMed Therapeutics US Inc
Ahead Therapeutics SL
Alexion Pharmaceuticals Inc
Amgen Inc
Beijing Mabworks Biotech Co Ltd
Bio-Thera Solutions Ltd
Biocad
Biogen Inc
Boston Pharmaceuticals Inc
CSPC NBP Pharmaceutical Co Ltd
CSPC Pharmaceutical Group Ltd
Endece LLC
EnhanX Biopharm Inc
F. Hoffmann-La Roche Ltd
Fundacio Clinic per a la Recerca Biomedica
Guangzhou Jiayue Pharmaceutical Technology Co Ltd
Guangzhou Lupeng Pharmaceutical Co Ltd
H. Lundbeck AS
ImCyse SA
ImmunAbs Inc
Imstem Biotechnology Inc
InnoCare Pharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Keio University
Lapix Therapeutics Inc
Merck KGaA
Mitsubishi Tanabe Pharma Corp
Nanjing IASO Biotherapeutics Co Ltd
NovelMed Therapeutics Inc
PlateletBio
RemeGen Co Ltd
Shanghai Pharmaceutical Group Co Ltd
SinoMab Bioscience Ltd
Tasly Biopharmaceuticals Co Ltd
Turgut Ilaclari AS
Zhejiang University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Neuromyelitis Optica (Devic's Syndrome) reports